IEC On-Demand Education
In effort to bring valuable information and education to a wider audience, the IEC continues to develop webcasts of the symposia taking place throughout the year. In each of these webcasts, leading experts in atopic dermatitis provide new insights and promote management through research, education, and patient/family care.
Please enjoy these complimentary webcasts. The IEC will announce new webcasts as they become available.
Prurigo Nodularis
- Define Prurigo Nodularis and its related nomenclature.
- Examine the pathophysiology and potential therapeutic targets of Prurigo Nodularis.
- Discuss the diagnosis and management of Prurigo Nodularis, to include oral therapies and emerging biologics.
New Developments in Atopic Dermatitis and Implications for the Atopic March
- Demonstrate diagnostic accuracy of atopic dermatitis, assess when to biopsy and when to refer patients for further evaluation
- Apply recent advances in AD pathogenesis, including immune dysregulation, barrier dysfunction and interpretation of differences between adults and children to better assess and treat patients with atopic dermatitis
- Optimize AD treatment selection using recent advances in emerging topical and systemic therapies
- Recognize and treat the most frequent infections associated with AD
- Acquire strategies to better counsel parents and patients on atopic dermatitis prevention
Single Cell Technologies Applicable to Atopic Eczema
- Single Cell Genomics Technologies: an Overview
- Contribution of Fibroblasts to the Pathogenesis of AD
- The Technology of Spatial Transcriptomics from a Clinical Standpoint
- Spatial Transcriptomics Applicable to AD
- New Minimally Invasive Techniques for Biomarker Discover
Customizing the Treatment of Atopic Dermatitis for Diverse Populations
- Personalized medicine in AD & adapting tape strips for use in pediatric populations
- Evaluation of patients with diverse ethnicities: Different severity scores among different populations
- Filaggrin gene mutations & AD in children: A focus and observations from the first study of its kind in India
- Dupilumab & JAK inhibitors in special populations
Microbiome
- Skin Microbiome Signatures in Atopic Dermatitis
- On-Person Adaptive Evolution of Staphylococcus aureus During Treatment for Atopic Dermatitis
- Heterogeneity in Cutaneous Infection Prevalence and Frequency by Timing of Atopic Dermatitis Onset
- Staphylococcus aureus Proteases Trigger Skin Inflammation via Eosinophil-Derived IL-17 Responses
- Infantile Eczema and Staphylococcus aureus Agr Mutations
- Host-Microbiome Metabolic Interactions in Atopic Dermatitis
- Botanical inhibitors of Staphylococcal Virulence: A New Path Toward Mitigating Atopic Dermatitis Severity?
What's new in Atopic Dermatitis?
- What’s new in AD prevention?
- What’s new in comorbidities?
- What’s new in pediatric AD?
- What’s new in topical treatments?
- What’s new in systemic treatments?
- What’s new in AD and infections/Staph Aureus?
Diagnosis and Management of Non-Atopic Forms of Dermatitis in Atopic Dermatitis Patients
- Pathophysiology of non-atopic forms of dermatitis
- Allergic contact dermatitis in AD patients
- Irritant contact dermatitis in AD patients
- AD patients with new-onset dermatitis on the face
- Patch testing in AD patients: impact of flares and system medications
Alopecia Areata and Atopic Dermatitis
- Pathogenesis of AD and Relevance to Alopecia Areata
- Epidemiology of Alopecia Areata and Atopic Comorbidities
- Novel treatments of Atopic Dermatitis (focus on biologics)
- Clinical Trails Awareness for the Eczema Community
- Alopecia Areata: Other Emerging Treatment Options
- Pediatric Alopecia Areata and Role of Atopy
- JAK inhibitors across Atopic Dermatitis and Alopecia Areata
Advanced Topics in Atopic Dermatitis
- Atopic Dermatitis: The Tale of a Success Story
- The Barrier abnormalities of AD and potential for prevention strategies
- Existing and Novel Topical Treatments for AD
- Current and New Systemic Treatments
- Ocular Manifestations of AD
- Pediatric Atopic Dermatitis: Children are more than little adults
- Epithelial Barrier Hypothesis for the Development of Allergic and Autoimmune Diseases
- Emerging Global and US Epidemiologic Trends in AD
- Comorbidities of AD and their Pathogenesis
Atopic Dermatitis Involving the Face and Sensitive Areas
- Allergic contact/irritant dermatitis
- Epidemiology and Burden of Facial AD
- Treatment of atopic dermatitis involving the face
- Dupilumab-associated facial skin changes
- Mechanisms of Sensitive Skin
- Differences in diagnosis and treatment in the context of ethnic skin
Human Models of Atopic Dermatitis
- Human Equivalent Models
- Genetic variation in Human models
- Environmental Exposures and Allergens
- Human Models in vivo
- Computational Models of Atopic Dermatitis
- Panel Discussion
Management of Pediatric Atopic Dermatitis: A Global Perspective
- Welcome & History of ISPD and IEC
- Management of Pediatric AD: A Global Presepecitve
- Setting the scene for what’s new in therapy?
- Atopic Dermatitis in Skin of Color
- The Role of the Microbiome in Atopic Dermatitis
- Skin Infections in Atopic Dermatitis
- The Importance of Patient Education and Strategies for Delivery – A Global Perspective
- Panel Discussion
Biomarkers
- Cytokines and chemokines as a possible biomarker in atopic dermatitis
- Atopic Dermatitis 3.0: from clinical phenotypes to biomarker based endophenotypes
- Treatment response biomarkers and minimally invasive skin biomarkers
- Fireside Chat Panel Discussion
Chronic Hand Eczema
- Chronic Hand Eczema: Epidemiology, Etiology and Classification
- How to Run a Hand Eczema Clinic
- Hand Eczema - Contact Dermatitis
- Tools to Measure Hand Eczema Severity
- Current Therapeutic Strategies, Phototherapy, and Systemic Therapy
- New Topical and Systemic Treatments for Chronic Hand Eczema
Novel Systemic Treatments for Atopic Dermatitis and Clinical Trial Design
- Optimizing Clinical Trial Design for AD drug development
- Novel Systemic Treatments in Pediatrics and Placebo Responses in Systemic Trials
- Monoclonal antibodies targeting Th2 receptors and cytokines (e.g. IL4R, IL-13 and IL-31)
- Monoclonal antibodies targeting epithelial-derived protein (e.g. IL-17C, IL-33 and TSLP)
- Monoclonal antibodies with other targets (e.g. OX40, IL-22 and IL-23) and biomarkers of disease response
- Systemic JAK inhibitors
- Topical JAK inhibitors
New Treatments for Atopic Dermatitis in Infants and Children
- Overview of Pediatric AD
- Mechanisms for Prevention of AD
- Topical Therapies
- Systemic Therapies
Management of AD Patients on Systemic Treatments during COVID-19
- COVID-19 and Pediatric AD Patients
- COVID-19 and Adult AD Patients
- COVID-19 New York Patients Atopic Dermatitis Topical Study Design
- SECURE-AD Registry
New Topical Developments and Preventive Mechanisms
- Atopic Dermatitis Topical Study Design
- Mechanisms for Prevention of AD
- PDE-4 Inhibitors
- Topical Therapies: Tapinarof and Beyond
Atopic Dermatitis Comorbidities
- Atopic Comorbidities (e.g., asthma, hay fever, food allergy)
- Cardiovascular Comorbidities (e.g., diabetes and CVD)
- Autoimmune Comorbidities (e.g., vitiligo, urticaria, AA, RA)
- Cutaneous Comorbidities (e.g., contact allergy, irritant contact dermatitis, occupational hand eczema, infections, skin cancer)
- Psychiatric Comorbidities (e.g., anxiety, depression, sleep disorders, ADHD)
- Economics and Healthcare in Atopic Dermatitis
|
